Skye Bioscience Statistics
Total Valuation
Skye Bioscience has a market cap or net worth of $123.95 million. The enterprise value is $75.74 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Skye Bioscience has 30.99 million shares outstanding. The number of shares has increased by 82.20% in one year.
| Current Share Class | 30.99M |
| Shares Outstanding | 30.99M |
| Shares Change (YoY) | +82.20% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 1.57% |
| Owned by Institutions (%) | 31.16% |
| Float | 18.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.84 |
| P/TBV Ratio | 2.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.09, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.09 |
| Quick Ratio | 5.85 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -72.75% and return on invested capital (ROIC) is -46.79%.
| Return on Equity (ROE) | -72.75% |
| Return on Assets (ROA) | -40.92% |
| Return on Invested Capital (ROIC) | -46.79% |
| Return on Capital Employed (ROCE) | -104.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.65M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Skye Bioscience has paid $5,400 in taxes.
| Income Tax | 5,400 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.22% in the last 52 weeks. The beta is 2.34, so Skye Bioscience's price volatility has been higher than the market average.
| Beta (5Y) | 2.34 |
| 52-Week Price Change | -33.22% |
| 50-Day Moving Average | 3.74 |
| 200-Day Moving Average | 2.89 |
| Relative Strength Index (RSI) | 61.73 |
| Average Volume (20 Days) | 289,265 |
Short Selling Information
The latest short interest is 2.67 million, so 8.61% of the outstanding shares have been sold short.
| Short Interest | 2.67M |
| Short Previous Month | 2.71M |
| Short % of Shares Out | 8.61% |
| Short % of Float | 14.34% |
| Short Ratio (days to cover) | 7.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -45.64M |
| Pretax Income | -42.28M |
| Net Income | -42.37M |
| EBITDA | -45.03M |
| EBIT | -45.64M |
| Earnings Per Share (EPS) | -$1.07 |
Full Income StatementBalance Sheet
The company has $48.59 million in cash and $367,540 in debt, giving a net cash position of $48.22 million or $1.56 per share.
| Cash & Cash Equivalents | 48.59M |
| Total Debt | 367,540 |
| Net Cash | 48.22M |
| Net Cash Per Share | $1.56 |
| Equity (Book Value) | 43.68M |
| Book Value Per Share | 1.41 |
| Working Capital | 42.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.37 million and capital expenditures -$1.57 million, giving a free cash flow of -$34.94 million.
| Operating Cash Flow | -33.37M |
| Capital Expenditures | -1.57M |
| Free Cash Flow | -34.94M |
| FCF Per Share | -$1.13 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Skye Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -82.20% |
| Shareholder Yield | -82.20% |
| Earnings Yield | -34.18% |
| FCF Yield | -28.19% |
Analyst Forecast
The average price target for Skye Bioscience is $15.50, which is 287.50% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.50 |
| Price Target Difference | 287.50% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 31.96% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:250.
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:250 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
